title: First-line treatment with hepatic arterial infusion plus capecitabine vs capecitabine alone for elderly patients with unresectable colorectal liver metastases.
abstract: This study aimed to compare the efficacy and safety of HAI fluoropyrimidine (FUDR)/capecitabine or single capecitabine as first-line treatment for elderly patients with unresectable colorectal liver metastases (CLMs). Fifty-one elderly patients with liver-only CLMs were eligible for enrollment. Patients were divided into HAI FUDR /capecitabine group and single capecitabine group randomly. The primary endpoint was median survival time (MST), defined as the time from the date of catheter implantation to the date of death or the date of the last follow-up. The secondary endpoint was objective antitumor response and adverse events. The HAI pump was implanted before chemotherapy. All patients received a 3-week cycle of oral capecitabin. In Group A, the RR and DCR were both 95.8%. In Group B, the RR and DCR were 48.1% and 81.5%, respectively. There was significant difference between the RRs of the 2 groups (P < 0.001). But there was no significant difference between the DCRs of the 2 groups (P = 0.053). There was a statistical difference between the MSTs of the 2 groups (18.5 vs.13 months, P = 0.0312). HAI FUDR combined with oral capecitabine as the first-line treatment for elderly patients with CLMs has promising efficacy and safety.
authors.affiliation: a Department of Oncology , The Third Affiliated Hospital of Soochow University Changzhou , China.|b Department of Biological Treatment , The Third Affiliated Hospital of Soochow University Changzhou , China.|c Jiangsu Engineering Research Center for Tumor Immunotherapy Changzhou , China.
authors.forename: Xiaodong
authors.initials: X
authors.lastname: Li
authors.affiliation: a Department of Oncology , The Third Affiliated Hospital of Soochow University Changzhou , China.|c Jiangsu Engineering Research Center for Tumor Immunotherapy Changzhou , China.
authors.forename: Liangrong
authors.initials: L
authors.lastname: Shi
authors.affiliation: a Department of Oncology , The Third Affiliated Hospital of Soochow University Changzhou , China.
authors.forename: Jun
authors.initials: J
authors.lastname: Wu
authors.affiliation: a Department of Oncology , The Third Affiliated Hospital of Soochow University Changzhou , China.
authors.forename: Mei
authors.initials: M
authors.lastname: Ji
authors.affiliation: a Department of Oncology , The Third Affiliated Hospital of Soochow University Changzhou , China.
authors.forename: Jiemin
authors.initials: J
authors.lastname: Zhao
authors.affiliation: a Department of Oncology , The Third Affiliated Hospital of Soochow University Changzhou , China.
authors.forename: Weiguang
authors.initials: W
authors.lastname: Qiang
authors.affiliation: d Department of Orthopedics , The Third Affiliated Hospital of Soochow University Changzhou , China.
authors.forename: Wenge
authors.initials: W
authors.lastname: Ding
authors.affiliation: b Department of Biological Treatment , The Third Affiliated Hospital of Soochow University Changzhou , China.|c Jiangsu Engineering Research Center for Tumor Immunotherapy Changzhou , China.
authors.forename: Jingting
authors.initials: J
authors.lastname: Jiang
authors.affiliation: e Department of Gastrointestinal Surgery , The Third Affiliated Hospital of Soochow University Changzhou , China.
authors.forename: Qicheng
authors.initials: Q
authors.lastname: Lu
authors.affiliation: a Department of Oncology , The Third Affiliated Hospital of Soochow University Changzhou , China.|b Department of Biological Treatment , The Third Affiliated Hospital of Soochow University Changzhou , China.|c Jiangsu Engineering Research Center for Tumor Immunotherapy Changzhou , China.
authors.forename: Changping
authors.initials: C
authors.lastname: Wu
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000069287:Capecitabine / Q000008:administration & dosage*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D005260:Female; D005467:Floxuridine / Q000008:administration & dosage*; D006499:Hepatic Artery; D006801:Humans; D007261:Infusions, Intra-Arterial; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000556:secondary; D008297:Male; D009362:Neoplasm Metastasis
chemical_list: D005467:Floxuridine; D000069287:Capecitabine
keywords: Capecitabine; colorectal liver metastases; floxuridine; hepatic arterial infusion